{"entity":{"id":"ndi-219216","kind":"drug","name":"NDI-219216","aka":[],"tldr":"NDI-219216 is an experimental small-molecule drug from Nimbus Wadjet in phase 2 trials, aimed at WRN helicase (MSI-high cancers).","summary":"NDI-219216 is a small-molecule drug developed by Nimbus Wadjet. Its target is WRN helicase (MSI-high cancers) (the sponsor names WRN helicase). The sponsor states: NDI-219216 is a highly selective, non-covalent small-molecule inhibitor of WRN helicase activity that triggers a DNA damage response and suppresses viability selectively in microsatellite instability-high (MSI-H) tumour cells, a synthetic-lethal approach. ClinicalTrials.gov describes the intervention as: NDI-219216 is a highly selective small molecule inhibitor of WRN helicase activity. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06898450, plans to enrol 134 participants with primary completion expected 2031-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of NDI-219216","url":"https://clinicaltrials.gov/search?intr=NDI-219216"},{"label":"Sponsor pipeline page","url":"https://nimbustx.com/pipeline/"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["wrn"],"drugs":[],"companies":["nimbus-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06898450"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"NDI-219216 is a highly selective, non-covalent small-molecule inhibitor of WRN helicase activity that triggers a DNA damage response and suppresses viability selectively in microsatellite instability-high (MSI-H) tumour cells, a synthetic-lethal approach.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ndi-219216/","neighbours":{"target":[{"id":"wrn","kind":"target","name":"WRN helicase (MSI-high cancers)","route":"/targets/wrn/"}],"company":[{"id":"nimbus-therapeutics","kind":"company","name":"Nimbus Therapeutics","route":"/companies/nimbus-therapeutics/"}],"trial":[{"id":"nct06898450","kind":"trial","name":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","route":"/trials/nct06898450/"}]}}